Chirurgia (Bucur). 2021 Oct;116(5):533-541. doi: 10.21614/chirurgia.116.5.533.
Sentinel Lymph node biopsy (SLNB) represents the standard approach in a newly diagnosed breast cancer for axillary staging in cases of clinical node negative. This represents a major prognostic factor and the biopsy of sentinel lymph node for early breast cancer is used as guidance in surgical and oncological treatment. Although for many decades, axillary lymph node dissection was the standard approach for breast cancer treatment and staging, this pathway was abandoned due to significant risk of lymphedema, infection, nerve and vessels injury or dysfunction of the shoulder. Therefore, significant improvement in the quality of life was seen for patients diagnosed with early breast cancer after SLNB was introduced as standard. The principle of SLNB is based on the hypothesis that tumor drains in the lymphatic system in an orderly manner and if the first lymphatic station is clear of disease, it is highly unlike that the tumor has spread further above. We present in our paper the indications with principles and difficulties in identification of sentinel node.
前哨淋巴结活检（SLNB）代表了临床淋巴结阴性的新诊断乳腺癌患者腋窝分期的标准方法。这是一个重要的预后因素，早期乳腺癌的前哨淋巴结活检可作为手术和肿瘤治疗的指导。尽管几十年来，腋窝淋巴结清扫术一直是乳腺癌治疗和分期的标准方法，但由于腋窝淋巴水肿、感染、神经和血管损伤或肩部功能障碍的风险显著，这种方法已被放弃。因此，在引入 SLNB 作为标准治疗方法后，早期乳腺癌患者的生活质量显著提高。SLNB 的原理基于这样的假设，即肿瘤在淋巴系统中有序地引流，如果第一个淋巴结没有疾病，那么肿瘤进一步扩散的可能性就非常小。我们在本文中介绍了前哨淋巴结的适应证、识别原则和困难。
